Gotham__Org Gotham White.png
MICRA

Multidimensional Impact of Cancer Risk Assessment

For patients who have undergone genetic testing for risk of cancer

 

Overview

The Multidimensional Impact of Cancer Risk Assessment (MICRA) is a tool to measure the specific
impact of result disclosure after genetic testing. The authors compared its performance with that of
questionnaires measuring general and cancer-specific distress. Participants (158 females) responded 1
month after they received genetic test results. They were divided into 4 standard clinical test result groups: BRCA1/2 positive, BRCA1/2 negative, panel negative, and true negative. Factor analysis
supported the formation of 3 subscales: Distress, Uncertainty, and Positive Experiences. All 3 MICRA subscales differentiated participants who were BRCA1/2 positive from the other 3 groups. MICRA thus helps identify subgroups of vulnerable genetic testing participants.

MEASURE NAME:

Multidimensional Impact of Cancer Risk Assessment (MICRA)

VERSION:

1

NUMBER OF ITEMS:

25

PATIENT POPULATION:

Patients 18 years and older who have received cancer-related genetic testing

RECALL PERIOD:

Past 7 days

RESPONSE SCALE:

4 point Likert-type scale

DATA COLLECTION:

Paper and electronic

ADMINISTRATION:

Self-administration and interview when applicable

SUBSCALE DOMAINS:

Distress, Uncertainty, Positive Experiences

TIME FOR COMPLETION:

Not available

SCORING:

Manual scoring template, some items are reverse scored. Subscale scores and total scores possible.

RELATED MEASURES:

Language Availability

Available translations of the MICRA can be obtained when licensing the measure. Users are not permitted to translate the MICRA without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the MICRA.

Please contact us for more information.

 
 

Licensing

Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.

Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.

To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.

 

Selected References

Cella D, Hughes C, Peterman A, Chang CH, Peshkin BN, Schwartz MD, Wenzel L, Lemke A, Marcus AC, Lerman C. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol. 2002 Nov;21(6):564-72.

 

Related Measures

FACT-G

Functional Assessment of Cancer Therapy - General

FACT-G7

Functional Assessment of Cancer Therapy – General – 7 Item Version

FANLTC

Functional Assessment of Non-Life Threatening Conditions

Gotham__Group-Gotham-White_SFW.png
Lauren Lent, DHA, MS
President, FACITtrans, LLC
Executive Director, FACIT.org
About Us
© 2020 FACIT.org 
Benjamin Arnold, MA
Executive Director, FACITtrans, LLC
Jason Bredle, MFA
Director, FACIT.org